Dominic Cuthbert

Tolero Pharmaceuticals aims to explore the potential combination therapy of its investigational agent alvocidib with AbbVie’s venetoclax for treating relapsed/refractory acute myeloid leukemia (AML). Alvocidib...

The Pharmaceutical Benefits Advisory Committee (PBAC) have recommended Orkambi to be listed on the Pharmaceutical Benefits Scheme in Australia for people ages six and...

The FDA has approved Bristol-Myers Squibb’s Opdivo as the first and only immuno-oncology treatment option for patients with previously treated metastatic small cell lung...